Kailera Therapeutics

Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape. The lead product candidate, ribupatide (also known as KAI-9531), is advancing in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.